Araştırma Makalesi

Prognosis in IDH-Mutant and IDH-wild type glioblastoma

Cilt: 43 Sayı: 3 30 Eylül 2021
Cumhuriyet Tıp Dergisi Kapak
Cumhuriyet Tıp Dergisi
PDF İndir
EN

Prognosis in IDH-Mutant and IDH-wild type glioblastoma

Öz

Glioblastoma (GBM) is the most common brain tumor in adults with a poor prognosis and predominantly astrocytic differentiation. GBM is classified according to the isocitrate dehydrogenase (IDH) mutation according to the World Health Organization (WHO) Brain Tumors 2016 classification. IDH-1 gene mutations are evaluated immunohistochemically (IHC) and molecular methods in current pathology laboratory practice.
The aim of this study was to determine the overall survival in GBM cases according to IDH-1 mutation status and Ki-67 proliferation index.
Total of 53 patients diagnosed as GBM between 2007-2020 in Sivas Cumhuriyet University Faculty of Medicine, Department of Pathology were evaluated. Disease-free median survival of 7 (13%) GBM patients with IDH mutation was 2 months (2-year survival 14%), disease-free median survival 9 months (2-year survival 24 %) in GBM IDH-wild type cases. In cases with a higher Ki-67 proliferation index, the median disease-free survival were shorter.
In conclusion statistically significant results could not be obtained between disease-free survival in GBM IDH-mutant type and GBM IDH-wild type. However, the mean Ki-67 proliferation index of GBM IDH-wild type cases was found to be much higher than GBM IDH-mutant cases. High Ki-67 proliferation index was found to be associated with a significantly shorter survival.

Anahtar Kelimeler

Destekleyen Kurum

Sivas Cumhuriyet Üniversitesi Bilimsel Araştırma Projeleri (CÜBAP)

Proje Numarası

T-902

Kaynakça

  1. 1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds). WHO Classification of Tumours of the Central Nervous System. 4th ed, IARC, Lyon 2016. WHO
  2. 2. Ostrom QT, Gittleman H, Truitt G, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. Neuro Oncol 2018; 20 Suppl
  3. 3. Chang SM, Parney IF, Huang W, et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA 2005; 293: 557.
  4. 4. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Eng l J Med 2009; 360: 765. 5. Gokden M. If it is not Glioblastoma then What is it? A Differential Diagnostic Review. Adv Anat Pathol. 2017 Nov; 24 (6): 379-391. doi: 10.1097/PAP.0000000000000170.
  5. 6. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma Groups Basedon 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med 2015; 372: 2499.
  6. 7. Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencingas a basis foran "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma an dglioblastoma. ActaNeuropathol 2015; 129: 133.
  7. 8. Gramatzki D, Dehler S, Rushing EJ, et all. Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to2009. Cancer. 2016 Jul 15; 122 (14): 2206-2215. doi: 10.1002/cncr.30023. Epub2016 Apr18.
  8. 9. Wirsching HG, Galanis E,Weeler M. Glioblastoma. Handb Clin Neurol 2016; 134: 381-397. doi: 10.1016/B978-0-12-802997-8.00023-2

Ayrıntılar

Birincil Dil

İngilizce

Konular

Sağlık Kurumları Yönetimi

Bölüm

Araştırma Makalesi

Yazarlar

Yayımlanma Tarihi

30 Eylül 2021

Gönderilme Tarihi

1 Haziran 2021

Kabul Tarihi

16 Ağustos 2021

Yayımlandığı Sayı

Yıl 2021 Cilt: 43 Sayı: 3

DOI

https://doi.org/10.7197/cmj.945850

IZ

https://izlik.org/JA72YU69BZ

Kaynak Göster

RIS / Bibtex
APA
Kılıç, E., Yeldir, N., Özüm, Ü., Yücel, B., Yılmaz, M., Özer, H., & Eğilmez, R. (2021). Prognosis in IDH-Mutant and IDH-wild type glioblastoma. Cumhuriyet Medical Journal, 43(3), 249-253. https://doi.org/10.7197/cmj.945850
AMA
1.Kılıç E, Yeldir N, Özüm Ü, vd. Prognosis in IDH-Mutant and IDH-wild type glioblastoma. CMJ. 2021;43(3):249-253. doi:10.7197/cmj.945850
Chicago
Kılıç, Eren, Neşe Yeldir, Ünal Özüm, vd. 2021. “Prognosis in IDH-Mutant and IDH-wild type glioblastoma”. Cumhuriyet Medical Journal 43 (3): 249-53. https://doi.org/10.7197/cmj.945850.
EndNote
Kılıç E, Yeldir N, Özüm Ü, Yücel B, Yılmaz M, Özer H, Eğilmez R (01 Eylül 2021) Prognosis in IDH-Mutant and IDH-wild type glioblastoma. Cumhuriyet Medical Journal 43 3 249–253.
IEEE
[1]E. Kılıç vd., “Prognosis in IDH-Mutant and IDH-wild type glioblastoma”, CMJ, c. 43, sy 3, ss. 249–253, Eyl. 2021, doi: 10.7197/cmj.945850.
ISNAD
Kılıç, Eren - Yeldir, Neşe - Özüm, Ünal - Yücel, Birsen - Yılmaz, Mukaddes - Özer, Hatice - Eğilmez, Reyhan. “Prognosis in IDH-Mutant and IDH-wild type glioblastoma”. Cumhuriyet Medical Journal 43/3 (01 Eylül 2021): 249-253. https://doi.org/10.7197/cmj.945850.
JAMA
1.Kılıç E, Yeldir N, Özüm Ü, Yücel B, Yılmaz M, Özer H, Eğilmez R. Prognosis in IDH-Mutant and IDH-wild type glioblastoma. CMJ. 2021;43:249–253.
MLA
Kılıç, Eren, vd. “Prognosis in IDH-Mutant and IDH-wild type glioblastoma”. Cumhuriyet Medical Journal, c. 43, sy 3, Eylül 2021, ss. 249-53, doi:10.7197/cmj.945850.
Vancouver
1.Eren Kılıç, Neşe Yeldir, Ünal Özüm, Birsen Yücel, Mukaddes Yılmaz, Hatice Özer, Reyhan Eğilmez. Prognosis in IDH-Mutant and IDH-wild type glioblastoma. CMJ. 01 Eylül 2021;43(3):249-53. doi:10.7197/cmj.945850